Phase Ib trial of AVL-292, a covalent inhibitor of Bruton's tyrosine kinase (Btk), in chronic lymphocytic leukemia (CLL) and B-non-Hodgkin lymphoma (B-NHL).
Year: 2012
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Jennifer R. Brown, Jeff Porter Sharman, Wael A. Harb, Kevin R. Kelly, Marshall T. Schreeder, John W. Sweetenham, Paul M. Barr, James M. Foran, Janice Lynn Gabrilove, Thomas J. Kipps, Shuo Ma, Susan Mary O'Brien, Erica Evans, Heather Lounsbury, Bruce A. Silver, Juswinder Singh, Kathryn Stiede, William Westlin, Steven Witowski, Daruka Mahadevan
Institutions: Dana-Farber Cancer Institute, Willamette Valley Cancer Institute and Research Center, Horizon Oncology Center, The University of Texas at San Antonio Health Science Center, Clearview Cancer Institute, Cleveland Clinic, University of Rochester Medicine, Mayo Clinic in Florida, Mayo Clinic Comprehensive Cancer Center (Florida), Icahn School of Medicine at Mount Sinai, Moores Cancer Center, Northwestern University, The University of Texas MD Anderson Cancer Center, University of Arizona Cancer Center
Language: English
Subfield: Genetics (clinical)
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2426028354